Published January 1, 2022 | Version v1
Publication

Additional file 2 of S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer

  • 1. Peking Union Medical College Hospital
  • 2. Chinese Academy of Medical Sciences & Peking Union Medical College
  • 3. The Ohio State University
  • 4. Southern University of Science and Technology
  • 5. Georgetown University Medical Center
  • 6. Georgetown University
  • 7. Dalian Medical University
  • 8. Northeast Forestry University
  • 9. Sheng Jing Hospital
  • 10. Xuzhou Medical College
  • 11. Chongqing University
  • 12. University of Rhode Island
  • 13. Yangzhou University
  • 14. Huazhong Agricultural University
  • 15. University of Chinese Academy of Sciences
  • 16. Peking University First Hospital
  • 17. Nanjing University
  • 18. Inner Mongolia University
  • 19. Liaoning Cancer Hospital & Institute
  • 20. Beijing University of Chemical Technology
  • 21. Henan Academy of Agricultural Sciences
  • 22. China University of Petroleum, Beijing
  • 23. Chinese Academy of Sciences
  • 24. Peking University
  • 25. Harbin Institute of Technology
  • 26. Hainan Medical University
  • 27. Central South University
  • 28. Huazhong University of Science and Technology
  • 29. United States Food and Drug Administration
  • 30. Beijing Academy of Agricultural and Forestry Sciences
  • 31. Hubei University of Medicine
  • 32. First Affiliated Hospital of Xi'an Jiaotong University
  • 33. Sun Yat-sen University
  • 34. Fifth Affiliated Hospital of Sun Yat-sen University
  • 35. First Affiliated Hospital of Liaoning Medical University
  • 36. Liaoning Medical University
  • 37. Lanzhou Veterinary Research Institute
  • 38. Wuhan University
  • 39. The Sixth People's Hospital of Shenyang
  • 40. National Institute for Communicable Disease Control and Prevention
  • 41. Jilin Medical University
  • 42. Jilin University
  • 43. Fudan University
  • 44. Chinese Center For Disease Control and Prevention
  • 45. Lexington VA Health Care System

Description

Additional file 2: Supplementary Table S2. The copy number variation of S6K1 gene (S6K1:CEP17 via ddPCR) in patients with low S6K1 expression.

⚠️ This is an automatic machine translation with an accuracy of 90-95%

Translated Description (Arabic)

الملف الإضافي 2: الجدول التكميلي S2. تباين عدد النسخ لجين S6K1 (S6K1: CEP17 عبر ddPCR) في المرضى الذين يعانون من انخفاض تعبير S6K1.

Translated Description (French)

Dossier complémentaire 2 : Tableau complémentaire S2. La variation du nombre de copies du gène S6K1 (S6K1 :CEP17 via ddPCR) chez les patients ayant une faible expression de S6K1.

Translated Description (Spanish)

Expediente adicional 2: Cuadro Complementario S2. La variación del número de copias del gen S6K1 (S6K1:CEP17 a través de ddPCR) en pacientes con baja expresión de S6K1.

Additional details

Additional titles

Translated title (Arabic)
يمنح الملف الإضافي 2 من تضخيم S6K1 مقاومة فطرية لمثبطات CDK4/6 من خلال تنشيط مسار c - Myc في المرضى الذين يعانون من سرطان الثدي الإيجابي لمستقبلات هرمون الاستروجين
Translated title (French)
Le dossier supplémentaire 2 de l'amplification S6K1 confère une résistance innée aux inhibiteurs de CDK4/6 en activant la voie c-Myc chez les patientes atteintes d'un cancer du sein à récepteurs d'œstrogènes positifs
Translated title (Spanish)
El archivo adicional 2 de la amplificación de S6K1 confiere resistencia innata a los inhibidores de CDK4/6 a través de la activación de la vía c-Myc en pacientes con cáncer de mama positivo para receptores de estrógeno

Identifiers

Other
https://openalex.org/W4394552119
DOI
10.6084/m9.figshare.20745204

GreSIS Basics Section

Is Global South Knowledge
Yes
Country
China